Menu
Not yet recruiting NCT06544070

Capillary Blood Accuracy

— Observational Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Entia Liberty System.
Who it may be relevant to
Registry conditions: Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Entia is a health technology company that has developed a blood testing device called Entia Liberty, which analyses blood collected by a finger prick. Entia is sponsoring this research study to compare the results from Entia Liberty finger prick tests to results from the gold-standard laboratory analyser that tests blood from the arm, port, or PICC line.

Interventions

  • Device Entia Liberty System
    Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.

Primary outcome measures

  • Validity of of the Liberty System for haematological parameters of interest: Hb, WBC, PLT, ANC [Time frame: Through study completion, up to 8 days per participant.]
  • Reliability of of the Liberty System for haematological parameters of interest: Hb, WBC, PLT, ANC [Time frame: Through study completion, up to 8 days per participant.]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years old at the time of study entry
  • Patients undergoing systemic anti-cancer therapy (SACT)
  • Patients capable of providing written informed consent
  • Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care

Additional inclusion criteria:

  • Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting
  • Phase 2 (Low count data): Neutrophil Count ≤ 1.5 x109/L within 24 hours preceding consenting

Exclusion criteria

  • History or current diagnosis of haematological malignancy
  • Inadequate use and understanding of the English language, requiring a translator

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06544070 · CTM-PRO-00028 · 347665

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗